Actively Recruiting
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Led by AstraZeneca · Updated on 2026-03-11
630
Participants Needed
99
Research Sites
423 weeks
Total Duration
On this page
Sponsors
A
AstraZeneca
Lead Sponsor
P
Parexel
Collaborating Sponsor
AI-Summary
What this Trial Is About
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.
CONDITIONS
Official Title
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB).
- WHO or ECOG performance status of 0 or 1.
- Adequate organ and bone marrow function.
- Provision of tumor samples (newly acquired or archival tumor tissue ≤ 6 months old) to confirm PD-L1, EGFR, or ALK status.
- Adequate pulmonary function.
You will not qualify if you...
- Sensitising EGFR mutations or ALK translocations.
- Baseline PD-L1 expression status <1% (Arms 6 and 7 only).
- Active or prior autoimmune or inflammatory disorders.
- Uncontrolled illnesses including hypertension, angina, arrhythmia, bleeding, serious gastrointestinal conditions, psychiatric illness, or social situations limiting compliance.
- History of another primary malignancy.
- Small-cell lung cancer or mixed small-cell lung cancer.
- History of active primary immunodeficiency.
- History or current non-infectious interstitial lung disease or pneumonitis requiring steroids.
- Preoperative radiotherapy planned.
- Need for pneumonectomy, segmentectomies, or wedge resections to achieve curative tumor removal.
- QTcF interval ≥ 470 ms.
- Medical contraindications to chemotherapy.
- Moderate or severe cardiovascular disease.
- Concurrent cancer chemotherapy, investigational, biologic, or hormonal therapy.
- Receipt of live attenuated vaccine within 30 days prior to first study dose.
- Prior exposure to immune-mediated therapies including anti-CTLA-4, anti-TIGIT, anti-PD-1, anti-PD-L1, anti-PD-L2, adenosine pathway agents, anti-NKG2A, anti-HLA-E, anti-LIF, TROP2 targeting ADCs, or other ADCs with TOP1 inhibitors.
- Use of immunosuppressive medication within 14 days before first study dose.
- Active or uncontrolled infections including HBA, HBV, HCV, and HIV.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 99 locations
1
Research Site
Little Rock, Arkansas, United States, 72205
Actively Recruiting
2
Research Site
Los Angeles, California, United States, 90095
Actively Recruiting
3
Research Site
Oakland, California, United States, 94611
Withdrawn
4
Research Site
New Haven, Connecticut, United States, 06510
Actively Recruiting
5
Research Site
Stuart, Florida, United States, 34994
Completed
6
Research Site
Gainesville, Georgia, United States, 30501
Completed
7
Research Site
Chicago, Illinois, United States, 60637
Actively Recruiting
8
Research Site
Baltimore, Maryland, United States, 21201
Withdrawn
9
Research Site
Baltimore, Maryland, United States, 21231
Actively Recruiting
10
Research Site
Boston, Massachusetts, United States, 02215
Actively Recruiting
11
Research Site
Saint Louis Park, Minnesota, United States, 55426
Completed
12
Research Site
Omaha, Nebraska, United States, 68124
Actively Recruiting
13
Research Site
Buffalo, New York, United States, 14263
Actively Recruiting
14
Research Site
Cleveland, Ohio, United States, 44195
Actively Recruiting
15
Research Site
Pittsburgh, Pennsylvania, United States, 15212
Actively Recruiting
16
Research Site
Chattanooga, Tennessee, United States, 37404
Actively Recruiting
17
Research Site
Memphis, Tennessee, United States, 38120
Actively Recruiting
18
Research Site
Nashville, Tennessee, United States, 37203
Withdrawn
19
Research Site
Nashville, Tennessee, United States, 37203
Actively Recruiting
20
Research Site
Nashville, Tennessee, United States, 37232
Actively Recruiting
21
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
22
Research Site
Houston, Texas, United States, 77090
Actively Recruiting
23
Research Site
Fairfax, Virginia, United States, 22031
Actively Recruiting
24
Research Site
Edmonds, Washington, United States, 98026
Actively Recruiting
25
Research Site
Seattle, Washington, United States, 98104
Actively Recruiting
26
Research Site
Ghent, Belgium, 9000
Actively Recruiting
27
Research Site
Ghent, Belgium, 9000
Completed
28
Research Site
Gilly, Belgium, 6060
Actively Recruiting
29
Research Site
Leuven, Belgium, 3000
Actively Recruiting
30
Research Site
Roeselare, Belgium, 8800
Actively Recruiting
31
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Completed
32
Research Site
Winnipeg, Manitoba, Canada, R3E 0V9
Actively Recruiting
33
Research Site
Montreal, Quebec, Canada, H2W 1S6
Actively Recruiting
34
Research Site
Montreal, Quebec, Canada, H2X 3E4
Actively Recruiting
35
Research Site
Avignon, France, 84902
Actively Recruiting
36
Research Site
Bobigny, France, 93009
Withdrawn
37
Research Site
Bordeaux, France, 33076
Actively Recruiting
38
Research Site
Limoges, France, 83000
Actively Recruiting
39
Research Site
Rennes, France, 35000
Actively Recruiting
40
Research Site
Rouen, France, 76031
Actively Recruiting
41
Research Site
Suresnes, France, 92150
Actively Recruiting
42
Research Site
Toulon, France, 83000
Actively Recruiting
43
Research Site
Kecskemét, Hungary, 6000
Actively Recruiting
44
Research Site
Székesfehérvár, Hungary, 8000
Actively Recruiting
45
Research Site
Tatabánya, Hungary, 2800
Completed
46
Research Site
Törökbálint, Hungary, 2045
Actively Recruiting
47
Research Site
Dublin, Ireland, D07 R2WY
Actively Recruiting
48
Research Site
Dublin, Ireland, D08 NHY1
Actively Recruiting
49
Research Site
Dublin, Ireland, D09 V2N0
Actively Recruiting
50
Research Site
Galway, Ireland, H91 YR71
Actively Recruiting
51
Research Site
Aviano, Italy, 33081
Actively Recruiting
52
Research Site
Brescia, Italy, 25123
Actively Recruiting
53
Research Site
Catanzaro, Italy, 88100
Withdrawn
54
Research Site
Florence, Italy, 50134
Actively Recruiting
55
Research Site
Genova, Italy, 16100
Actively Recruiting
56
Research Site
Meldola, Italy, 47014
Actively Recruiting
57
Research Site
Milan, Italy, 20162
Actively Recruiting
58
Research Site
Monza, Italy, 20900
Actively Recruiting
59
Research Site
Padova, Italy, 35128
Actively Recruiting
60
Research Site
Perugia, Italy, 06156
Actively Recruiting
61
Research Site
Pisa, Italy, 56124
Actively Recruiting
62
Research Site
Roma, Italy, 00144
Actively Recruiting
63
Research Site
Rozzano, Italy, 20089
Actively Recruiting
64
Research Site
Lisbon, Portugal, 1099-023
Actively Recruiting
65
Research Site
Lisbon, Portugal, 1169-050
Actively Recruiting
66
Research Site
Lisbon, Portugal, 1400-038
Actively Recruiting
67
Research Site
Lisbon, Portugal, 1500-650
Actively Recruiting
68
Research Site
Porto, Portugal, 4099-001
Withdrawn
69
Research Site
Porto, Portugal, 4100-180
Completed
70
Research Site
Porto, Portugal, 4200-072
Actively Recruiting
71
Research Site
Busan, South Korea, 48108
Completed
72
Research Site
Chungcheongbuk-do, South Korea, 28644
Withdrawn
73
Research Site
Seongnam-si, South Korea, 13496
Actively Recruiting
74
Research Site
Seoul, South Korea, 03080
Actively Recruiting
75
Research Site
Seoul, South Korea, 05505
Actively Recruiting
76
Research Site
Suwon, South Korea, 16247
Actively Recruiting
77
Research Site
Suwon, South Korea, 440-746
Actively Recruiting
78
Research Site
A Coruña, Spain, 15006
Actively Recruiting
79
Research Site
Alicante, Spain, 03010
Actively Recruiting
80
Research Site
Barcelona, Spain, 08036
Actively Recruiting
81
Research Site
Barcelona, Spain, 8035
Actively Recruiting
82
Research Site
Córdoba, Spain, 14004
Actively Recruiting
83
Research Site
Madrid, Spain, 28040
Actively Recruiting
84
Research Site
Majadahonda, Spain, 28250
Actively Recruiting
85
Research Site
Málaga, Spain, 29010
Actively Recruiting
86
Research Site
Reus, Spain, 43204
Actively Recruiting
87
Research Site
Seville, Spain, 41009
Actively Recruiting
88
Research Site
Terrassa, Spain, 08221
Actively Recruiting
89
Research Site
Valencia, Spain, 46010
Actively Recruiting
90
Research Site
Liuying, Taiwan, 736
Actively Recruiting
91
Research Site
New Taipei City, Taiwan, 235
Actively Recruiting
92
Research Site
Tainan, Taiwan, 70403
Actively Recruiting
93
Research Site
Taipei, Taiwan, 10002
Actively Recruiting
94
Research Site
Taipei, Taiwan, 11217
Actively Recruiting
95
Research Site
Ankara, Turkey (Türkiye), 06010
Actively Recruiting
96
Research Site
Ankara, Turkey (Türkiye), 06500
Actively Recruiting
97
Research Site
Ankara, Turkey (Türkiye), 06800
Actively Recruiting
98
Research Site
Istanbul, Turkey (Türkiye), 34722
Actively Recruiting
99
Research Site
Izmir, Turkey (Türkiye), 35575
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
A
AstraZeneca Lung Cancer Study Locator Service
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here